Lymphoma

Phase 2 ELARA Trial Meets Primary End Point in R/R Follicular Lymphoma
August 04, 2020
ByHannah Slater

Novartis announced that the study met its primary end point of complete response rate in patients with relapsed or refractory follicular lymphoma.

Caron A. Jacobson, MD, on What Patients Should Know About the Phase 2 ZUMA-5 Study
July 14, 2020
ByCaron A. Jacobson, MD

The expert in hematology discussed what patients should know about the study, which evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

John Kuruvilla, MD, Discusses Toxicities Observed in the Phase 3 KEYNOTE-204 Study
July 12, 2020
ByJohn Kuruvilla, MD

The expert in hematology highlighted the toxicities reported in this trial and explained the differences observed between the 2 drugs studied.